Doog, I think you are too hard on yourself. right now we all are in disbelief for what Odidi has done to this company. However to say you wish you had sold after the adcomm the price opened at $1.140 and went down from there. So to say you wish you had sold back then means you d not see the PPS recovering above that $1.40.
Honestly, I do not see things being that gloom and doom. I think we will be CFP by 1QE18. Seroquel has had a late start and I think competitors already had contracts locked up and it just takes time to build the market share. Par also still has two doses to release! we have seen continued improvement quarter over quarter in revenue and that will continue.
Next, I think we see at least 1 ANDA approval within the next 6 months, which is partnered with MNK. I also think within that same time the company releases news of the additional tests which should be positive.
The Markman hearing is set for April. at which point afterwards, we will get direction from the court on how he is leaning towards the litigation. unless Odidi did infringe, which lets face it all his patents have to been for something LOL, we then get a good indication of a favorable outcome and possibly even early settlement from Purdue. But even without early settlement, just a favorable PR indicating a favorable outcome from that hearing will be a big boost.
at which point, in my mind, I would be surprised f we are not trading at least at the $2.50 to $3 range in the next 6 months to say sometime 2QE18. So,in my mind we hold. AND in this time frame continue to put pressure on the board to hold them accountable for Odidis failure as CEO. His inability to partner and his failure to grasp the gravity of allowing something like Regabatin to sit on a shelf the last two years and for failure to find a market for 2 other approved drugs.
